Insulin glulisine in the management of diabetes

Satoru Yamada1,21Diabetes Center, Kitasato Institute Hospital, Tokyo, Japan; 2Department of Internal Medicine, Keio University School of Medicine, Tokyo, JapanAbstract: Insulin glulisine is appealing in principle, but the advantages of this drug over the other rapid-acting insulin analogs are still...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Satoru Yamada
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2009
Materias:	Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/81881391964b4acc90bccbf4114255c3
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:81881391964b4acc90bccbf4114255c3
record_format	dspace
spelling	oai:doaj.org-article:81881391964b4acc90bccbf4114255c32021-12-02T05:04:14ZInsulin glulisine in the management of diabetes1178-7007https://doaj.org/article/81881391964b4acc90bccbf4114255c32009-07-01T00:00:00Zhttp://www.dovepress.com/insulin-glulisine-in-the-management-of-diabetes-a3337https://doaj.org/toc/1178-7007Satoru Yamada1,21Diabetes Center, Kitasato Institute Hospital, Tokyo, Japan; 2Department of Internal Medicine, Keio University School of Medicine, Tokyo, JapanAbstract: Insulin glulisine is appealing in principle, but the advantages of this drug over the other rapid-acting insulin analogs are still relatively unknown. The frequency of hypoglycemia, convenience in the timing of administration, and improvements in terms of HbA1c seem similar among the rapid-acting insulin analogs, including insulin glulisine. Only properly randomized long-term clinical studies with insulin glulisine will reveal the true value of this novel insulin analog.Keywords: insulin analog, rapid-acting insulin, trometamol, polysorbate 20 Satoru YamadaDove Medical PressarticleSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol 2009, Iss default, Pp 111-115 (2009)
institution	DOAJ
collection	DOAJ
language	EN
topic	Specialties of internal medicine RC581-951
spellingShingle	Specialties of internal medicine RC581-951 Satoru Yamada Insulin glulisine in the management of diabetes
description	Satoru Yamada1,21Diabetes Center, Kitasato Institute Hospital, Tokyo, Japan; 2Department of Internal Medicine, Keio University School of Medicine, Tokyo, JapanAbstract: Insulin glulisine is appealing in principle, but the advantages of this drug over the other rapid-acting insulin analogs are still relatively unknown. The frequency of hypoglycemia, convenience in the timing of administration, and improvements in terms of HbA1c seem similar among the rapid-acting insulin analogs, including insulin glulisine. Only properly randomized long-term clinical studies with insulin glulisine will reveal the true value of this novel insulin analog.Keywords: insulin analog, rapid-acting insulin, trometamol, polysorbate 20
format	article
author	Satoru Yamada
author_facet	Satoru Yamada
author_sort	Satoru Yamada
title	Insulin glulisine in the management of diabetes
title_short	Insulin glulisine in the management of diabetes
title_full	Insulin glulisine in the management of diabetes
title_fullStr	Insulin glulisine in the management of diabetes
title_full_unstemmed	Insulin glulisine in the management of diabetes
title_sort	insulin glulisine in the management of diabetes
publisher	Dove Medical Press
publishDate	2009
url	https://doaj.org/article/81881391964b4acc90bccbf4114255c3
work_keys_str_mv	AT satoruyamada insulinglulisineinthemanagementofdiabetes
_version_	1718400661030174720

Insulin glulisine in the management of diabetes

Ejemplares similares